1. In Vivo

2022 Global Biopharma R&D Productivity And Growth Ranking

Another Turbulent Year For Global Biopharma

 
• By Markus Thunecke, Erika Kuchen, and Alexander Wallroth

The R&D productivity of the top 30 largest biopharma companies decreased slightly from 2021 to 2022 and the sector saw the lowest number of FDA approvals in the past 10 years. 

up and down arrows
• Source: Shutterstock

Russia invading Ukraine, global supply chain disruptions, energy shortages in Europe and widespread inflation worries have created a perfect storm in which investors naturally gravitate towards less riskier opportunities than biopharma.

In line with this shift in investor sentiment, the US XBI biotech index decreased by a further 28% during 2022,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ESG

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.